Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop - 28/02/23

Doi : 10.1016/S1470-2045(22)00742-2

Lalitha K Shankar, MD ^a,⁎ , Heiko Schöder, ProfMD ^d, Elad Sharon, MD ^c, Jedd Wolchok, ProfMD ^e, Michael V Knopp, ProfMD ^f, Richard L Wahl, ProfMD ^g, Benjamin M Ellingson, ProfPhD ^h, Nathan C Hall, MD ⁱ, Martin J Yaffe, ProfPhD ^j, Alexander J Towbin, ProfMD ^k, Michael D Farwell, MD ⁱ, Daniel Pryma, ProfMD ⁱ, Tina Young Poussaint, ProfMD ^l, Chadwick L Wright, MD ^f, Lawrence Schwartz, ProfMD ^m, Mukesh Harisinghani, ProfMD ⁿ, Umar Mahmood, ProfMD ⁿ, Anna M Wu, ProfPhD ^o, David Leung, MD ^p, Elisabeth G E de Vries, ProfMD ^q, Ying Tang, PhD ^r, Gillian Beach, PhD ^s, Steven A Reeves, PhD ^b
^a Clinical Trials Branch, National Cancer Institute, Rockville, MD, USA
^b Coordinating Center for Clinical Trials, National Cancer Institute, Rockville, MD, USA
^c Investigational Drug Branch, National Cancer Institute, Rockville, MD, USA
^d Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
^e Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA
^f Department of Radiology, Ohio State University, Columbus, OH, USA
^g Department of Radiology, Washington University, St Louis, MO, USA
^h Department of Radiological Sciences, University of California Los Angeles, Los Angeles, CA, USA
ⁱ Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA
^j Medical Biophysics, University of Toronto, Toronto, ON, Canada
^k Department of Radiology and Medical Imaging, Cincinnati Children’s Hospital, Cincinnati, OH, USA
^l Department of Radiology, Boston Children’s Hospital, Boston, MA, USA
^m Department of Radiology, Columbia University, New York, NY, USA
ⁿ Department of Radiology, Massachusetts General Hospital, Boston, MA, USA
^o Department of Immunology & Theranostics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA
^p Bristol Myers Squibb, Princeton, NJ, USA
^q Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands
^r CCS Associates, McLean, VA, USA
^s The Emmes Company, Rockville, MD, USA

^*Correspondence to: Dr Lalitha K Shankar, Clinical Trials Branch, National Cancer Institute, Rockville, MD 20852-4910, USAClinical Trials BranchNational Cancer InstituteRockvilleMD20852-4910USA

Summary

As the immuno-oncology field continues the rapid growth witnessed over the past decade, optimising patient outcomes requires an evolution in the current response-assessment guidelines for phase 2 and 3 immunotherapy clinical trials and clinical care. Additionally, investigational tools—including image analysis of standard-of-care scans (such as CT, magnetic resonance, and PET) with analytics, such as radiomics, functional magnetic resonance agents, and novel molecular-imaging PET agents—offer promising advancements for assessment of immunotherapy. To document current challenges and opportunities and identify next steps in immunotherapy diagnostic imaging, the National Cancer Institute Clinical Imaging Steering Committee convened a meeting with diverse representation among imaging experts and oncologists to generate a comprehensive review of the state of the field.

Le texte complet de cet article est disponible en PDF.

Plan

Background

Current clinical landscape and standard of care

The global landscape of immunotherapy oncology trials and NCI strategy

Clinical characterisation and response assessment in immunotherapy

Evolving tumour metrics: from morphology to metabolism

Modified RECIST metrics: facilitating validation of consensus guidelines for response assessment of immunotherapy

Modified RANO (mRANO)

Advanced imaging techniques

PERCIST and FDG-PET or CT in guiding immunotherapy trials

Advanced analytics for CT images: radiomics

Novel MRI contrast agent: ferumoxytol-enhanced MRI

Molecular imaging agents in clinical development

PET agent targeting granzyme B

PET agent targeting CD8⁺ T cells

PET agents targeting PD-1 and PD-L1

Additional PET agents targeting PD-1, PD-L1, and CD8

Discussion

Conclusion

Search strategy and selection criteria

Export

Vol 24 - N° 3

P. e133-e143 - mars 2023 Retour au numéro

Article précédent

Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium
Stephanie G C Kroeze, Matea Pavic, Karin Stellamans, Yolande Lievens, Carlotta Becherini, Marta Scorsetti, Filippo Alongi, Umberto Ricardi, Barbara Alicja Jereczek-Fossa, Paulien Westhoff, Jasna But-Hadzic, Joachim Widder, Xavier Geets, Samuel Bral, Maarten Lambrecht, Charlotte Billiet, Igor Sirak, Sara Ramella, Ivaldi Giovanni Battista, Sergi Benavente, Almudena Zapatero, Fabiola Romero, Thomas Zilli, Kaouthar Khanfir, Hossein Hemmatazad, Berardino de Bari, Desiree N Klass, Shaukat Adnan, Heike Peulen, Juan Salinas Ramos, Michiel Strijbos, Sanjay Popat, Piet Ost, Matthias Guckenberger

| Article suivant

Sclerotic bone metastasis as initial manifestation of lung adenocarcinoma in a patient with SLE
Ruchi Mittal, Debashis Maikap, Pallavi Mishra, Prasanta Padhan, Sangram Panda

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop - 28/02/23

Summary

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL